This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pich, A. Articles by Chiusa, L. Search for Related Content PubMed PubMed Citation Articles by Pich, A. Articles by Chiusa, L. Social Bookmarking                            What's this?

Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival

From the Department of Biomedical Sciences and Human Oncology, Section of Pathology, University of Turin; and the Division of Pathology, S. Giovanni Hospital, Turin, Italy.

Address reprint requests to Achille Pich, MD, Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Via Santena 7, I-10126 Torino, Italy; email pich{at}molinette.unito.it

PURPOSE: To investigate the prognostic value of biomarkers in male breast carcinoma (MBC).

PATIENTS AND METHODS: Fifty patients (mean age, 62.2 years) with invasive ductal carcinoma were retrospectively studied. All patients received surgery; 35 had adjuvant postoperative therapy. The median follow-up was 59 months (range, 1 to 230 months). c-myc, c-erbB-2, p53, and bcl-2 proteins were immunohistochemically detected on sections from formalin-fixed, paraffin-embedded tissues using 9E11, CB11, DO7, and bcl-2 124 monoclonal antibodies (mAbs). Estrogen, progesterone, and androgen receptors were detected using specific mAbs. Cell proliferation was assessed by MIB-1 mAb.

RESULTS: In univariate analysis, c-myc, c-erbB-2, and p53 protein overexpression was significantly correlated with prognosis. The median survival was 107 months for c-myc–negative and 52 months for c-myc–positive patients (P = .01), 96 months for c-erbB-2–negative and 39 months for c-erbB-2–positive patients (P = .02), and 100 months for p53-negative and 33 months for p53-positive patients (P = .0008). Tumor histologic grade (P = .01), tumor size (P = .02), patient age at diagnosis (P = .03), and MIB-1 scores (P = .0004) also had prognostic value. In multivariate analysis, only c-erbB-2 and p53 immunoreactivity retained independent prognostic significance. All nine patients who did not express c-erbB-2 and p53 proteins were alive after 58 months, whereas none of the 14 patients expressing both proteins survived at 61 months follow-up (P = .0002).

CONCLUSION: Overexpression of c-myc, c-erbB-2, and p53 proteins may be regarded as an additional prognostic factor in MBC. The combination of c-erbB-2 and p53 immunoreactivity can stratify patients into different risk groups.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]

				A. Mavi, T. F. Cermik, M. Urhan, H. Puskulcu, S. Basu, J. Q. Yu, H. Zhuang, B. Czerniecki, and A. Alavi The Effects of Estrogen, Progesterone, and C-erbB-2 Receptor States on 18F-FDG Uptake of Primary Breast Cancer Lesions J. Nucl. Med., August 1, 2007; 48(8): 1266 - 1272. [Abstract] [Full Text] [PDF]

				S. Omori, S. Yoshida, S. H. Kennedy, K. Negoro, S. Hamana, D. H. Barlow, and T. Maruo Polymorphism at Codon 72 of the p53 Gene Is Not associated With Endometriosis in a Japanese Population Reproductive Sciences, May 1, 2004; 11(4): 232 - 236. [Abstract] [PDF]

				J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398. [Abstract] [Full Text] [PDF]

				E. Kwiatkowska, M. Teresiak, V. Filas, A. Karczewska, D. Breborowicz, and A. Mackiewicz BRCA2 Mutations and Androgen Receptor Expression as Independent Predictors of Outcome of Male Breast Cancer Patients Clin. Cancer Res., October 1, 2003; 9(12): 4452 - 4459. [Abstract] [Full Text] [PDF]

				J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy Oncologist, August 1, 2003; 8(4): 307 - 325. [Abstract] [Full Text] [PDF]

				J.-L. Merlin, M. Barberi-Heyob, and N. Bachmann In vitro comparative evaluation of trastuzumab (Herceptin(R)) combined with paclitaxel (Taxol(R)) or docetaxel (Taxotere(R)) in HER2-expressing human breast cancer cell lines Ann. Onc., November 1, 2002; 13(11): 1743 - 1748. [Abstract] [Full Text] [PDF]

				S. H. Giordano, A. U. Buzdar, and G. N. Hortobagyi Breast Cancer in Men Ann Intern Med, October 15, 2002; 137(8): 678 - 687. [Abstract] [Full Text] [PDF]

				G. Curigliano, M. Colleoni, G. Renne, G. Mazzarol, R. Gennari, G. Peruzzotti, F. de Braud, C. Robertson, E. Maiorano, P. Veronesi, et al. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay Ann. Onc., June 1, 2002; 13(6): 895 - 902. [Abstract] [Full Text] [PDF]

				Y. S. Kim, S. N. Konoplev, F. Montemurro, E. Hoy, T. L. Smith, G. Rondon, R. E. Champlin, A. A. Sahin, and N. T. Ueno HER-2/neu Overexpression As a Poor Prognostic Factor for Patients with Metastatic Breast Cancer undergoing High-dose Chemotherapy with Autologous Stem Cell Transplantation Clin. Cancer Res., December 1, 2001; 7(12): 4008 - 4012. [Abstract] [Full Text] [PDF]